Empagliflozin and Major Renal Outcomes in Heart Failure

Authors:
Publisher website
Google Scholar
Abstract
Sodium–glucose cotransporter 2 inhibitors reduce the risk of serious adverse renal outcomes in type 2 diabetes, but the renal effects of these drugs in patients with heart failure remain uncertain. Although empagliflozin and dapagliflozin have been reported to slow the rate of decline in the estimated glomerular filtration rate (eGFR),1,2 changes in the eGFR slope may not predict the effects of these drugs on major renal outcomes.3
Funding Information
  • Boehringer Ingelheim
  • Eli Lilly and Company